Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation

Pol Arch Intern Med. 2018 Jun 29;128(6):386-388. doi: 10.20452/pamw.4284. Epub 2018 Jun 29.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Erdheim-Chester Disease / drug therapy*
  • Erdheim-Chester Disease / genetics
  • Erdheim-Chester Disease / metabolism
  • Humans
  • Imidazoles / pharmacology
  • Imidazoles / therapeutic use*
  • Male
  • Middle Aged
  • Mutation, Missense*
  • Oximes / pharmacology
  • Oximes / therapeutic use*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics*
  • Treatment Outcome

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib